Neuroplasticity Marker GAP-43 Emerges as Potential Alzheimer's Disease Driver

What New Insights into Alzheimer's Disease Does This Study Offer?

Vanderbilt researchers have identified growth-associated protein-43 (GAP-43) as a potential key driver in Alzheimer's disease pathogenesis, according to a longitudinal study published in Alzheimer's & Dementia. The 4-year observational study of 161 older adults found that cerebrospinal fluid (CSF) levels of GAP-43, a marker of neuroplasticity, strongly predicted changes in core Alzheimer's disease biomarkers, particularly in individuals with established risk factors for dementia.

The study represents a significant advancement in understanding the mechanisms underlying Alzheimer's disease progression by demonstrating how increased neuroplastic activity may contribute to both amyloid and tau pathologies. This research shifts focus from simply targeting the end-stage protein accumulations to considering the upstream processes that may initiate the pathological cascade, potentially opening new avenues for therapeutic intervention and early diagnosis.

Could Overactive Neuroplasticity be a Culprit in Alzheimer's Pathogenesis?

Alzheimer's disease remains one of medicine's most challenging conditions, with limited treatment options despite decades of research targeting amyloid-β plaques and tau tangles. The Vanderbilt Memory and Aging Project team, led by investigators from the Vanderbilt Center for Cognitive Medicine, pursued a novel hypothesis that excessive neuroplasticity—the brain's ability to reorganize neural connections—might be a driving factor in disease development, particularly when combined with known risk factors like APOE ε4 genotype or cerebrovascular dysfunction.

"We found strong support linking increased neuroplastic activity to the pathological cascade of AD," noted the study authors. "Higher levels of CSF GAP-43 at baseline were cross-sectionally associated with higher CSF Aβ42, a finding driven largely by individuals at increased cerebrovascular risk, potentially reflecting an initial role of increased neuroplasticity in generating an overproduction of amyloid." Over time, high baseline GAP-43 levels predicted decreasing CSF Aβ42, suggesting that initially overproduced soluble amyloid was transitioning into brain plaque formation—a hallmark of Alzheimer's pathology.

Particularly striking were the findings that GAP-43 associations with phosphorylated tau (p-tau) and total tau were significantly stronger in individuals with established risk factors for Alzheimer's disease, including female sex, mild cognitive impairment, APOE ε4 carriers, and those already showing evidence of amyloid pathology. This suggests that in vulnerable populations, neuroplasticity-related processes may accelerate the development of tau pathology, the protein abnormality most closely linked to cognitive decline.

How Could These Discoveries Impact Alzheimer's Therapeutics?

The study's approach represents a departure from traditional biomarker research in Alzheimer's disease, which has typically focused on direct measurement of amyloid and tau proteins. By examining GAP-43 as an upstream marker of neuroplastic activity, researchers may have identified a process that precedes the protein accumulations typically targeted by therapeutic interventions. This could have significant implications for drug development programs at companies like Biogen, Eli Lilly, and Eisai, which have invested heavily in anti-amyloid approaches with mixed clinical success.

The findings also align with growing interest in synaptic health markers among diagnostic companies. While blood-based biomarkers for amyloid and tau are advancing rapidly toward clinical implementation, markers of neuroplasticity and synaptic function could provide complementary information for earlier detection and more precise patient stratification in clinical trials.

What Are the Future Implications for Alzheimer's Treatment and Diagnosis?

"These results suggest that increased neuroplastic activity, especially when in the context of known AD risk factors, is a key driver of the pathogenesis of AD pathology, including both amyloid and tau proteinopathies," the researchers concluded. "Our findings that associations are far stronger in individuals with common AD risk factors further suggest that increased neuroplastic activity driving the pathogenesis of AD is a potentially unifying theory."

Looking ahead, the study results may guide development of novel therapeutics targeting neuroplastic mechanisms or biomarker panels incorporating GAP-43 for earlier disease detection. However, the researchers acknowledged limitations, including the predominantly white, well-educated study population and the need for validation in larger, more diverse cohorts. Additional research will be needed to determine whether modulating neuroplastic activity could prevent or slow the progression of Alzheimer's pathology.

Industry Context: This research emerges as the Alzheimer's disease landscape undergoes significant transformation, with the recent approvals of amyloid-targeting therapies lecanemab (Leqembi) and donanemab generating renewed industry investment. However, the modest clinical benefits of these drugs highlight the need for complementary approaches targeting different disease mechanisms. Biomarkers that can identify patients earlier in the disease process and predict progression remain critical for clinical trial success and eventual market differentiation. The identification of neuroplasticity as a potential driver of pathology adds a new dimension to the complex biology of Alzheimer's disease that could influence future drug discovery and development strategies.

Summary

Vanderbilt researchers have identified growth-associated protein-43 (GAP-43) as a potential key driver in Alzheimer's disease pathogenesis through a 4-year longitudinal study of 161 older adults. The research demonstrates that elevated cerebrospinal fluid levels of GAP-43, a marker of neuroplasticity, strongly predicted changes in core Alzheimer's biomarkers, particularly amyloid-β and tau proteins. The study suggests that excessive neuroplastic activity—the brain's ability to reorganize neural connections—may contribute to both amyloid plaque formation and tau pathology, especially in individuals with established risk factors such as APOE ε4 genotype, female sex, mild cognitive impairment, or cerebrovascular dysfunction. This represents a significant shift from traditional approaches that focus on targeting end-stage protein accumulations to examining upstream processes that may initiate the pathological cascade. The findings indicate that higher baseline GAP-43 levels were associated with increased soluble amyloid production, which subsequently transitioned into brain plaque deposits over time. The associations between GAP-43 and tau pathology were particularly strong in vulnerable populations, suggesting that neuroplasticity-related processes may accelerate disease progression in at-risk individuals. These discoveries could have important implications for therapeutic development, potentially opening new avenues for drugs targeting neuroplastic mechanisms rather than solely focusing on amyloid clearance. The research also suggests potential for developing biomarker panels incorporating GAP-43 for earlier disease detection and more precise patient stratification in clinical trials. While the study had limitations, including a predominantly white, well-educated cohort requiring validation in more diverse populations, it offers a potentially unifying theory for Alzheimer's pathogenesis that links increased neuroplastic activity with the development of both major protein abnormalities characteristic of the disease.